Scipher Medicine announced that it has entered into a multi-disease area collaboration with Ionis Pharmaceuticals. In the collaboration, Ionis is responsible for advancing, developing and commercializing oligonucleotide therapies directed to targets discovered by Scipher’s Spectra platform.
During the collaboration, Scipher will use its Spectra platform and proprietary dataset of patient molecular data to identify novel targets for specific patient populations. Under the terms of the agreement, Ionis can advance targets identified by Scipher. Scipher and Ionis will also leverage the Spectra platform and proprietary dataset to identify patient subgroups more likely to benefit from therapy, which has potential to decrease time to drug approval through targeted clinical trials. Under terms of the agreement, Scipher will be eligible to receive milestone payments for the achievement of certain milestones, and royalties on net sales of collaboration products.
“The collaboration with Scipher is part of Ionis’ strategy to invest in precision genomic initiatives that enable new avenues for target discovery, which we believe can help accelerate the development of potentially transformative therapies for patients with unmet needs,” said Eric E. Swayze, Ph.D., executive vice president of research at Ionis.
“Our Spectra platform is a unique engine driving the development of precision therapeutics and our partnership with Ionis further validates its potential to transform patient care,” Scipher Medicine CEO Alif Saleh said. “Collaborating with a leader in RNA-based therapies is a natural extension of our approach to leveraging precision therapeutics to treat complex diseases.”
SOURCE: Businesswire